{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:09:52Z","timestamp":1789567792860,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.diabres.2025.112008","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:48:16Z","timestamp":1737593296000},"page":"112008","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Effects of silymarin on insulin resistance and sensitivity: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"220","author":[{"given":"Shao","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengya","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"42","key":"10.1016\/j.diabres.2025.112008_b0005","doi-asserted-by":"crossref","first-page":"11644","DOI":"10.1021\/acs.jafc.0c04791","article-title":"Health benefits of Silybum marianum: phytochemistry, pharmacology, and applications","volume":"68","author":"Wang","year":"2020","journal-title":"J Agric Food Chem"},{"key":"10.1016\/j.diabres.2025.112008_b0010","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/978-3-319-41342-6_2","article-title":"Silymarin and its role in chronic diseases","volume":"929","author":"Neha","year":"2016","journal-title":"Adv Exp Med Biol"},{"issue":"16","key":"10.1016\/j.diabres.2025.112008_b0015","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27165327","article-title":"Mechanistic insights into the pharmacological significance of silymarin","volume":"27","author":"Wadhwa","year":"2022","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.diabres.2025.112008_b0020","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/0002-8703(68)90114-2","article-title":"The congenital cardiovascular anomalies underlying \u201creversed coarctation\u201d","volume":"75","author":"Chesler","year":"1968","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.diabres.2025.112008_b0025","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/hep.25772","article-title":"Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis","volume":"56","author":"Loomba","year":"2012","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.diabres.2025.112008_b0030","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/jgh.13264","article-title":"Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis","volume":"31","author":"Ballestri","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.diabres.2025.112008_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.cld.2004.04.006","article-title":"Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease","volume":"8","author":"Choudhury","year":"2004","journal-title":"Clin Liver Dis"},{"issue":"3","key":"10.1016\/j.diabres.2025.112008_b0040","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1590\/1414-431X20122551","article-title":"Effect and the probable mechanisms of silibinin in regulating insulin resistance in the liver of rats with non-alcoholic fatty liver","volume":"46","author":"Yao","year":"2013","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.diabres.2025.112008_b0045","article-title":"A review of the botany, phytochemistry, pharmacology, synthetic biology and comprehensive utilization of Silybum marianum","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.diabres.2025.112008_b0050","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.trsl.2015.08.002","article-title":"Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence","volume":"167","author":"Federico","year":"2016","journal-title":"Transl Res"},{"issue":"3","key":"10.1016\/j.diabres.2025.112008_b0055","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.metabol.2012.08.005","article-title":"In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not","volume":"62","author":"Younossi","year":"2013","journal-title":"Metabolism"},{"issue":"8","key":"10.1016\/j.diabres.2025.112008_b0060","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.diabres.2025.112008_b0065","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22020191","article-title":"Silymarin\/silybin and chronic liver disease: a marriage of many years","volume":"22","author":"Federico","year":"2017","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.diabres.2025.112008_b0070","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/ptr.6361","article-title":"Safety and toxicity of silymarin, the major constituent of milk thistle extract: an updated review","volume":"33","author":"Soleimani","year":"2019","journal-title":"Phytother Res"},{"key":"10.1016\/j.diabres.2025.112008_b0075","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.phymed.2018.03.050","article-title":"Lower glycemic indices and lipid profile among type 2 diabetes mellitus patients who received novel dose of Silybum marianum (L.) Gaertn. (silymarin) extract supplement: a triple-blinded randomized controlled clinical trial","volume":"44","author":"Ebrahimpour-Koujan","year":"2018","journal-title":"Phytomedicine"},{"issue":"12","key":"10.1016\/j.diabres.2025.112008_b0080","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126403","article-title":"Role of insulin in health and disease: an update","volume":"22","author":"Rahman","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.diabres.2025.112008_b0085","doi-asserted-by":"crossref","first-page":"15","DOI":"10.18388\/abp.2014_853","article-title":"Role of pro-inflammatory cytokines of pancreatic islets and prospects of elaboration of new methods for the diabetes treatment","volume":"62","author":"Cie\u015blak","year":"2015","journal-title":"Acta Biochim Pol"},{"issue":"12","key":"10.1016\/j.diabres.2025.112008_b0090","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/nm.3705","article-title":"Glycemic control in diabetes is restored by therapeutic manipulation of cytokines that regulate beta cell stress","volume":"20","author":"Hasnain","year":"2014","journal-title":"Nat Med"},{"issue":"47","key":"10.1016\/j.diabres.2025.112008_b0095","doi-asserted-by":"crossref","first-page":"42723","DOI":"10.1021\/acsomega.2c04140","article-title":"Silymarin-functionalized selenium nanoparticles prevent LPS-induced inflammatory response in RAW264.7 cells through downregulation of the PI3K\/Akt\/NF-\u03baB pathway","volume":"7","author":"Mi","year":"2022","journal-title":"ACS Omega"},{"issue":"8","key":"10.1016\/j.diabres.2025.112008_b0100","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1021\/acs.jnatprod.5b00288","article-title":"Silymarin Suppresses Cellular Inflammation By Inducing Reparative Stress Signaling","volume":"78","author":"Lovelace","year":"2015","journal-title":"J Nat Prod"},{"key":"10.1016\/j.diabres.2025.112008_b0105","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.biopha.2017.06.018","article-title":"Silymarin prevents NLRP3 inflammasome activation and protects against intracerebral hemorrhage","volume":"93","author":"Yuan","year":"2017","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"10.1016\/j.diabres.2025.112008_b0110","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1080\/13880209.2016.1199042","article-title":"Silymarin improved diet-induced liver damage and insulin resistance by decreasing inflammation in mice","volume":"54","author":"Guo","year":"2016","journal-title":"Pharm Biol"},{"issue":"12","key":"10.1016\/j.diabres.2025.112008_b0115","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1007\/s10620-018-5268-0","article-title":"Silybin alleviates hepatic steatosis and fibrosis in NASH mice by inhibiting oxidative stress and involvement with the Nf-\u03baB pathway","volume":"63","author":"Ou","year":"2018","journal-title":"Dig Dis Sci"},{"issue":"1","key":"10.1016\/j.diabres.2025.112008_b0120","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1210\/en.2004-0850","article-title":"Silymarin protects pancreatic beta-cells against cytokine-mediated toxicity: implication of c-Jun NH2-terminal kinase and janus kinase\/signal transducer and activator of transcription pathways","volume":"146","author":"Matsuda","year":"2005","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.diabres.2025.112008_b0125","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/med.21599","article-title":"Inducible nitric oxide synthase: regulation, structure, and inhibition","volume":"40","author":"Cinelli","year":"2020","journal-title":"Med Res Rev"},{"issue":"1","key":"10.1016\/j.diabres.2025.112008_b0130","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14010045","article-title":"The beneficial additive effect of Silymarin in metformin therapy of liver steatosis in a Pre-diabetic model","volume":"14","author":"H\u00fcttl","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.diabres.2025.112008_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109721","article-title":"Silybin ameliorates hepatic lipid accumulation and modulates global metabolism in an NAFLD mouse model","volume":"123","author":"Sun","year":"2020","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"10.1016\/j.diabres.2025.112008_b0140","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ptr.6282","article-title":"Metabolic effect of berberine-silymarin association: A meta-analysis of randomized, double-blind, placebo-controlled clinical trials","volume":"33","author":"Fogacci","year":"2019","journal-title":"Phytother Res"},{"key":"10.1016\/j.diabres.2025.112008_b0145","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/5147468","article-title":"Silymarin in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled Trials","volume":"2016","author":"Voroneanu","year":"2016","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.diabres.2025.112008_b0150","first-page":"812","article-title":"Effect of silymarin supplementation on glycemic control, lipid profile and insulin resistance in patients with type 2 diabetes mellitus","volume":"3","author":"Elgarf","year":"2015","journal-title":"Int J Adv Res"},{"issue":"8","key":"10.1016\/j.diabres.2025.112008_b0155","doi-asserted-by":"crossref","first-page":"e6099","DOI":"10.5812\/hepatmon.6099","article-title":"Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic Fatty liver disease: a randomized controlled pilot study","volume":"12","author":"Hajiaghamohammadi","year":"2012","journal-title":"Hepat Mon"},{"issue":"12","key":"10.1016\/j.diabres.2025.112008_b0160","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/ptr.1988","article-title":"The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial","volume":"20","author":"Huseini","year":"2006","journal-title":"Phytother Res"},{"issue":"4","key":"10.1016\/j.diabres.2025.112008_b0165","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0168-8278(97)80255-3","article-title":"Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients","volume":"26","author":"Velussi","year":"1997","journal-title":"J Hepatol"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725000221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725000221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T11:29:22Z","timestamp":1738409362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822725000221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":33,"alternative-id":["S0168822725000221"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112008","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of silymarin on insulin resistance and sensitivity: A systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112008"}}